PMID- 28263701
OWN - NLM
STAT- MEDLINE
DCOM- 20170731
LR  - 20181202
IS  - 1527-1315 (Electronic)
IS  - 0033-8419 (Linking)
VI  - 284
IP  - 2
DP  - 2017 Aug
TI  - Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial 
      Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.
PG  - 583-592
LID - 10.1148/radiol.2017161975 [doi]
AB  - Purpose To identify early biomarkers for the prediction of the therapeutic 
      response in patients with hepatocellular carcinoma (HCC) treated with 
      transarterial chemoembolization (TACE) and sorafenib (referred to as TACE plus 
      sorafenib) and establish an effective prognostic nomogram. Materials and Methods 
      The study was approved by the institutional ethics review boards at both 
      participating centers. This retrospective study included all patients with HCC 
      who underwent TACE plus sorafenib therapy between January 2010 and December 2013 
      at two institutions. On the basis of the overall survival (OS), early biomarkers 
      were identified with univariate and multivariate analyses; then, a prognostic 
      nomogram was established and internally validated by using the concordance c 
      statistic. Results Ninety-seven patients (mean age, 55.0 years; range, 27-89 
      years) were included. Of these patients, 84 (86.6%) were men. The median OS was 
      25.7 months. After univariate and multivariate analyses, the onset of 
      sorafenib-induced hypertension and/or dermatologic adverse events (AEs) (grade 
      >/=2) within the first month of sorafenib initiation were demonstrated as 
      independent predictors of OS. The median OS of patients with either of the two 
      independent risk factors was 32.2 months, which was significantly longer than for 
      those patients without (19.8 months; P = .005). Survival analyses showed that the 
      earlier the AEs (sorafenib-related dermatologic AEs or hypertension) occurred, 
      the better the outcome of the combination therapy. A prognostic nomogram was 
      established and showed high accuracy of the nomogram with the c statistic of 
      0.73. Conclusion The early onset of hypertension and/or sorafenib-related 
      dermatologic AEs are early biomarkers for the clinical prognosis of patients with 
      HCC treated with TACE plus sorafenib. ((c)) RSNA, 2017.
FAU - Zhong, Bin-Yan
AU  - Zhong BY
AD  - From the Department of Radiology, Zhong-Da Hospital, Medical School, Southeast 
      University, 87 Dingjiaqiao Road, Nanjing 210009, China (B.Y.Z., L.C., H.D.Z., 
      G.J.T.); and Department of Interventional Radiology, First Affiliated Hospital of 
      Soochow University, Suzhou, China (C.F.N.).
FAU - Ni, Cai-Fang
AU  - Ni CF
AD  - From the Department of Radiology, Zhong-Da Hospital, Medical School, Southeast 
      University, 87 Dingjiaqiao Road, Nanjing 210009, China (B.Y.Z., L.C., H.D.Z., 
      G.J.T.); and Department of Interventional Radiology, First Affiliated Hospital of 
      Soochow University, Suzhou, China (C.F.N.).
FAU - Chen, Li
AU  - Chen L
AD  - From the Department of Radiology, Zhong-Da Hospital, Medical School, Southeast 
      University, 87 Dingjiaqiao Road, Nanjing 210009, China (B.Y.Z., L.C., H.D.Z., 
      G.J.T.); and Department of Interventional Radiology, First Affiliated Hospital of 
      Soochow University, Suzhou, China (C.F.N.).
FAU - Zhu, Hai-Dong
AU  - Zhu HD
AD  - From the Department of Radiology, Zhong-Da Hospital, Medical School, Southeast 
      University, 87 Dingjiaqiao Road, Nanjing 210009, China (B.Y.Z., L.C., H.D.Z., 
      G.J.T.); and Department of Interventional Radiology, First Affiliated Hospital of 
      Soochow University, Suzhou, China (C.F.N.).
FAU - Teng, Gao-Jun
AU  - Teng GJ
AD  - From the Department of Radiology, Zhong-Da Hospital, Medical School, Southeast 
      University, 87 Dingjiaqiao Road, Nanjing 210009, China (B.Y.Z., L.C., H.D.Z., 
      G.J.T.); and Department of Interventional Radiology, First Affiliated Hospital of 
      Soochow University, Suzhou, China (C.F.N.).
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20170306
PL  - United States
TA  - Radiology
JT  - Radiology
JID - 0401260
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Contrast Media)
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
CIN - Radiology. 2017 Sep;284(3):919-921. PMID: 28825885
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*therapeutic use
MH  - Biomarkers, Tumor/analysis
MH  - Carcinoma, Hepatocellular/diagnostic imaging/pathology/*therapy
MH  - *Chemoembolization, Therapeutic
MH  - China
MH  - Combined Modality Therapy
MH  - Contrast Media
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/diagnostic imaging/pathology/*therapy
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Niacinamide/*analogs & derivatives/therapeutic use
MH  - Phenylurea Compounds/*therapeutic use
MH  - Retrospective Studies
MH  - Sorafenib
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
EDAT- 2017/03/07 06:00
MHDA- 2017/08/02 06:00
CRDT- 2017/03/07 06:00
PHST- 2017/03/07 06:00 [pubmed]
PHST- 2017/08/02 06:00 [medline]
PHST- 2017/03/07 06:00 [entrez]
AID - 10.1148/radiol.2017161975 [doi]
PST - ppublish
SO  - Radiology. 2017 Aug;284(2):583-592. doi: 10.1148/radiol.2017161975. Epub 2017 Mar 
      6.